APO-LEFLUNOMIDE TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

LEFLUNOMIDE

から入手可能:

APOTEX INC

ATCコード:

L04AK01

INN（国際名）:

LEFLUNOMIDE

投薬量:

10MG

医薬品形態:

TABLET

構図:

LEFLUNOMIDE 10MG

投与経路:

ORAL

パッケージ内のユニット:

30

処方タイプ:

Prescription

治療領域:

DISEASE-MODIFYING ANTIRHEUMATIC AGENTS

製品概要:

Active ingredient group (AIG) number: 0140182001; AHFS:

認証ステータス:

APPROVED

承認日:

2004-09-08

製品の特徴

_APO-LEFLUNOMIDE (Leflunomide Tablets) _
_ _
_ Page 1 of 73 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
APO-LEFLUNOMIDE
Leflunomide Tablets
Tablets, 10 mg and 20 mg, Oral
Apotex Standard
Antirheumatic, Immunomodulator Agent
ATC Code: L04AA13
APOTEX INC.
150 Signet Drive
Toronto, Ontario
M9L 1T9
Date of Initial Authorization:
September 8, 2004
Date of Revision:
July 24, 2023
Submission Control Number: 272007
_APO-LEFLUNOMIDE (Leflunomide Tablets) _
_ _
_Page 2 of 73 _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS
07/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
................................................................................................
2
TABLE OF CONTENTS
.................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................................
4
1
INDICATIONS
................................................................................................................
4
1.1
Pediatrics
.....................................................................................................................
4
1.2
Geriatrics
......................................................................................................................
4
2
CONTRAINDICATIONS
...................................................................................................
4
4
DOSAGE AND ADMINISTRATION
...................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
............................................................ 5
4.4
Administration
.............................................................................................................
6
4.5
Missed Dose
.................................................................................................................
6
5